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Background/Aims: To assess the durability of protec-
tive hepatitis B surface antibody (anti-HBs) titers in HIV-
infected patients who responded to double-dose hepatitis 
B virus (HBV) rescue vaccination. Methods: A retrospective 
chart review was performed for HIV-infected patients who 
received the double-dose HBV rescue vaccination at 0-, 1-, 
and 2-month intervals after they had failed conventional 
HBV vaccination series. A protective antibody response was 
deﬁ  ned as an anti-HBs titer ≥10 mIU/mL. Results: Of 54 HIV-
infected patients who received a double-dose HBV rescue 
vaccination, 44 patients (81.5%) had a positive response 
and achieved protective anti-HB titers. Of the 44 patients 
who developed protective anti-HB titers, 33 patients received 
an evaluation of their anti-HB titers 12 months later. Of the 
33 patients, 19 (57.6%) had persistent protective anti-HB 
titers (persistent responders, PR), and 14 patients (42.4%) 
lost their protective anti-HB titers (nonpersistent responders, 
NPR). There were significantly more patients who had an 
undetectable HIV viral load (<50 copies/mL) at baseline and 
follow-up in the PR group (11/19, 57.9%) than in the NPR 
group (3/14, 21.4%, p=0.036). Logistic regression analysis 
showed that an undetectable HIV viral load at baseline and fol-
low-up (odds ratio, 12.973; 95% conﬁ  dence interval, 1.189 to 
141.515; p=0.036) was associated with PR. Conclusions: Pro-
tective anti-HB titers may decrease over time after successful 
double-dose HBV rescue vaccination in HIV-infected patients. 
HIV viral load suppression could improve the persistence of 
anti-HB titers. (Gut Liver 2012;6:86-91)
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INTRODUCTION
Co-infection with HIV and hepatitis B virus (HBV) is com-
mon; in the Western world, chronic HBV infection has been 
found in 6% to 14% among HIV-positive patients.
1,2 Chronic 
co-infection with HBV and HIV can lead to increased rates of 
liver-related morbidity (cirrhosis, hepatocellular carcinoma) and 
mortality.
3,4 Prevention of HBV infection is therefore essentially 
important in the setting of HIV-infection. The success rate of 
HBV vaccine, however, is much lower in HIV-infected patients 
as compared with healthy immunocompetent individuals. 90% 
to 95% of healthy adult individuals develop protective anti-
HBV antibody, whereas only 20% to 70% of the HIV-infected 
patients develop protective anti-HBV antibody after a conven-
tional standard dose of HBV vaccination at 0-1-6 monthly in-
tervals.
5 Contributing factors associated with nonresponsiveness 
to HBV vaccination in HIV-infected patients include ongoing 
HIV-viremia, impaired humoral and cellular immunity, HCV 
co-infection, and increasing age.
6-10 The most effective strategy 
for maximizing HBV-vaccine response in HIV-infected patients 
remains unknown. Administering doubled HBV vaccine dose, 
i.e., from 20 to 40 μg, has been tried in several studies with 
improved overall success rates of 36.6% to 89.5%.
11-15 In our ex-
perience, double-dose HBV rescue vaccination (40 μg HBV vac-
cination at 0-1-2 monthly intervals) achieved more than 80% 
seroconversion rates in HIV-infected patients who had failed 
to respond with conventional standard dose HBV vaccination 
(20 μg HBV vaccination at 0-1-6 monthly intervals with or 
without additional 20 μg HBV booster vaccination).
16 Also, it is 
important to point out that HIV co-infection decreases hepatitis 
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and conventionally vaccinated individuals.
17,18 Few data exist 
to assess the persistence of protective anti-HBs titers after suc-
cessful double-dose HBV rescue vaccination in the setting of 
HIV-infection. We reviewed anti-HBs titers a year later in HIV-
infected patients who had responded to double-dose HBV rescue 
vaccination.
MATERIALS AND METHODS
A retrospective medical-chart review study was conducted 
in our center. HIV-infected patients who had failed to develop 
protective anti-HBs after three or more standard conventional 
dose HBV vaccine (20 μg HBV vaccination at 0-1-6 monthly 
intervals with or without additional 20 μg HBV booster vacci-
nation) were identified and were given double-dose HBV rescue 
vaccination, (40 μg –20 μg/mL in each deltoid–) (Recombivax 
HB
® (Merck & Co., Inc., Whitehouse Station, NJ, USA) at 0-1-
2 monthly intervals. The vaccination schedule was based on a 
previous study, in which 0-1-2 monthly intervals of standard 
dose recombinant HBV vaccination resulted in a faster and also 
identical seroconversion rate to the standard dose recombinant 
HBV vaccination at 0-1-6 monthly intervals.
19 Patients who de-
veloped protective anti-HBs titers of ≥10 mIU/mL after double-
dose HBV rescue vaccination were classified as double-dose 
HBV rescue vaccination responders. These patients had anti-HBs 
titers assessment 12 months later.
Demographic characteristics, presence of hepatitis C virus 
(HCV) antibody, CD4 T-cell count, HIV RNA viral load, and use 
of highly active antiretroviral therapy (HAART) were reviewed 
at baseline –the time of first double-dose HBV rescue vaccina-
tion (at 0 month out of 0-1-2 monthly interval), and at one year 
follow-up, 12 months after completion of the double-dose HBV 
rescue vaccination series. Patients who retained anti-HBs titers 
of ≥10 mIU/mL at one year follow-up were classified as per-
sistent responders (PR) while patients with decreased anti-HBs 
titers of <10 mIU/mL were defined as nonpersisent responders 
(NPR).
Statistical analysis was performed using SPSS version 15.0 
for Windows (SPSS Inc., Chicago, IL, USA). Dichotomous vari-
ables were compared using Pearson χ
2 test or Fisher’s exact test. 
For continuous variables, Mann-Whitney test was used. Mul-
tivariate analysis by logistic regression was used to determine 
factors associated with successful PR. Odds ratio (OR) and 95% 
confidence interval (CI) were calculated. A p-value less than 0.05 
was considered to be statistically significant. 
This study was approved by Institutional Review Board at St. 
Luke’s-Roosevelt Medical Center, New York, NY, USA. 
RESULTS
The medical records of HIV-infected patients followed in our 
center between January 2004 and October 2010 were reviewed. 
Fifty-four patients received three double-dose HBV rescue vac-
cine at 0-1-2 monthly intervals after failure to develop protec-
tive anti-HBs with three or more conventional standard dose 
HBV vaccinations. The study population consisted of 41 males 
(75.9%) with a median age of 45 years. Hispanics and Blacks 
were the predominant ethnic groups (31/54, 57.4% and 15/54, 
27.8%, respectively). Homosexual men (men who have sex with 
men, MSM) were the major HIV-risk group, 30/54 of patients, 
55.6%. Nine patients (9/54, 16.7%) had chronic HCV infection. 
At the start of the double-dose HBV rescue vaccination series, 
49 patients (49/54, 90.7%) were on HAART. The median CD4 
T-cell count was 433 cell/  mm
3 (interquartile range [IQR], 328 
to 645 cell/mm
3) and 20 patients (20/54, 35.7%) had CD4 T-cell 
count >500 cell/mm
3. The median Log10 HIV viral load was 1.699 
(IQR, 1.699 to 2.358) and 30 patients (30/54, 53.6%) had HIV 
viral load <50 copies/mL. Forty-four patients (44/54, 81.5%) 
Table 1. Baseline Characteristics at the First Double-Dose HBV Rescue 
Vaccination and Double-Dose HBV Rescue Vaccine Response Rate
Characteristic Value
Total number of patients 54
Age median (IQR)    45 (37-50)
Sex 
  Female 
  Male 
Ethnicity
  White 
  Hispanic 
  Black 
 13 (24.1)
 41 (75.9)
 
   8 (14.8)
 31 (57.4)
 15 (27.8) 
HIV risk factor
  Hetero
  IVDU 
  MSM 
 18 (33.3)
   6 (11.1)
 30 (55.6)
Hepatitis C co-infection
  Hepatitis C positive     9 (16.7)
HAART
  On HAART    49 (90.7)
CD4 T-cell count median (IQR) 
  Patients with CD4 >500 
      433 (328-645)
  20 (35.7)
Log10 HIV viral load median (IQR)
  Patients with HIV viral load <50 
1.699 (1.699-2.358)
  30 (53.6) 
Double dose HBV rescue vaccine responders    44 (81.5)
Values are presented as median (IQR) or number (%).
HBV, hepatitis B virus; IQR, interquartile range; Hetero, heterosexual 
contact; IVDU, intravenous drug abuse; MSM, men who have sex 
with men; HAART, highly active antiretroviral therapy; CD4 T-cell 
cell count cells/mm
3, HIV viral load copies/mL; Double-dose HBV 
rescue vaccine responders, patients who developed protective anti-
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developed protective anti-HBs after completion of three double-
dose HBV vaccination series (double-dose HBV rescue vaccine 
responders). The baseline characteristics of patients at the start 
of double-dose HBV rescue vaccination are shown in Table 1.
Thirty-three of 44 double-dose HBV rescue vaccine respond-
ers had follow-up evaluation at one year after the last vaccine 
dose. Nineteen of the 33 double-dose HBV rescue vaccine re-
sponders (19/33, 57.6%) were found to have persistent levels of 
protective anti-HBs ≥10 mIU/mL and they were classified as PR. 
Fourteen patients (14/33, 42.4%) lost their protective anti-HBs 
at one year follow-up were defined as NPR. These are shown in 
Fig. 1. We compared the PR and NPR groups and there was no 
significant difference in terms of median CD4 T-cell count at 
baseline or at follow-up. Also the proportions of patients who 
had CD4 T-cell count >500 cell/mm
3 both at baseline and one 
year follow-up were not different; 4/19, 21.1% in PR group and 
3/14, 21.4% in NPR group (p=1.000). Although there was no 
significant difference in terms of median Log10 HIV viral load at 
baseline and follow-up between the two groups, the proportion 
of patients who had undetectable HIV viral load <50 copies/
mL both at baseline and one year follow-up was significantly 
higher in PR group (11/19, 57.9%) than in NPR group (3/14, 
21.4%) (p=0.036). The median of total number of overall HBV 
vaccinations including conventional standard dose HBV vaccine 
and double-dose HBV rescue vaccine was 6.0 (IQR, 6.0  to 7.0) 
for PR group and 6.0 (IQR, 6.0 to 6.3) for NPR group without 
significant difference (p=0.360) as shown in the Table 2.
A multivariate logistic regression analysis was performed us-
ing the variables of sex, HIV risk factors, presence of HCV anti-
body, receipt of HAART, CD4 T-cell count, and HIV viral load. 
Successful HIV viral load suppression defined by undetectable 
HIV viral load <50 copies/mL both at baseline and follow-up (OR, 
12.973; 95% CI, 1.189 to 141.515; p=0.036) was found to be as-
sociated with PR among HIV-infected double-dose HBV vaccine 
recipients as shown in Table 3. 
DISCUSSION
Our study showed an impressive response rate, 81.5%, of 
double-dose HBV rescue vaccination series in HIV-infected pa-
tients who had prior not responded to conventional HBV vac-
cination. However, levels of protective anti-HBs titer decreased 
over a year. 57.6% of double-dose HBV rescue vaccine respond-
ers were noted to have persistence of protective anti-HBs titer at 
one-year follow-up. Our findings are consistent with a previous 
study in which a high serologic response rate with double-dose 
HBV vaccination was observed, however, 63% of the responders 
had persistence of protective anti-HBs titer at 12 months.
14 Also 
results of our study correspond with the results of earlier study 
by Cooper et al.,
15 in which 89.5% of HIV-infected patients who 
received double-dose HBV vaccination developed protective 
anti-HBs titer, and persistence of seroprotective anti-HBs titer 
was 60% at 24 months of follow-up. Of note, Cooper et al.
15 ob-
served improved durability of the protective anti-HBs titers with 
the adjuvant CPG 7909 (>80% of patients at 42 to 60 months) 
compared to those generated by double-dose HBV vaccination 
without the adjuvant.
We observed that persistence of protective anti-HBs titers in 
HIV-infected patients at 1 year after double-dose HBV rescue 
vaccination was associated with HIV viral load suppression. 
Fig. 1. Double-dose hepatitis B virus 
(HBV) rescue vaccination and evalu-
ation of the durability of protective 
HBV surface antibody (anti-HBs) 
titers. 
HBVV DD, double-dose hepatitis B 
virus rescue vaccination at 0-, 1-, 
and 2-month intervals; HBVV SD, 
standard-dose hepatitis B virus vac-
cination at 0-, 1-, and 6-month in-
tervals with or without an additional 
standard-dose hepatitis B booster 
vaccination; PR, persistent respond-
ers; NPR, nonpersistent responders. Kim JH, et al: Analysis at One-year Follow-up  89
Furthermore our logistic regression analysis supports the role of 
HIV suppression as an important predictor of persistent anti-HBs 
titers. Previous studies have also demonstrated that development 
of anti-HBs responses following HBV vaccination of HIV-infect-
ed patients was associated with undetectable HIV viral load.
6,20 
Lower hepatitis B-specific memory B-cell responses, altered B-
cell and memory B-cell phenotypes, and reduced memory B-cell 
proliferative capacity were observed in HIV viremic patients fol-
lowing HBV vaccination.
21 Increased regulatory T cells in HIV-
infected patients were found to be associated with nonresponse 
to HBV vaccine.
22 In addition, an expansion of regulatory T cells 
has been reported in HIV-infected patients with high HIV viral 
load.
23 Our results in conjuncture with aforementioned literature 
further support the notion that maintaining optimal HIV load 
suppression after double-dose HBV rescue vaccination may play 
a critical role in persistence of protective anti-HBs titers. 
The long-term protective effect of HBV vaccine in HIV-
infected patients remains unknown. A recent multicenter ob-
servational cohort study of 11,632 person-years of follow-up 
demonstrated that HIV-infected patients who had achieved a 
response to HBV vaccine with protective anti-HBs titers ≥10 
mIU/mL had a 50% reduced risk of HBV infection compared to 
those with nonresponse to HBV vaccine. Of the patients with an 
initial positive HBV vaccine response, risk of HBV infection was 
Table 2. Demographic and Clinical Characteristics at One-Year 
Follow-Up after Completion of Three Double-Dose Hepatitis B Rescue 
Vaccinations by Two Groups of Persistent Responders (PR) and Non-
Persistent Responders (NPR)   
Characteristic
PR (n=19; 
19/33, 57.6%)
NPR (n=14; 
14/33, 42.4%)
p-value
Age median (IQR)     42 (39–48)     47 (39–52) 0.201
Sex
   Female 
   Male 
   3 (15.8)
 16 (84.2)
   4 (28.6)
 10 (71.4)
0.422
Ethnicity
   White 
   Hispanic 
   Black 
   5 (26.3)
 11 (57.9)
   3 (15.8)
1 (7.1)
 6 (42.9)
 7 (50.0)
 0.209
 0.393
 0.057
HIV risk factor
   Hetero 
   IVDU 
   MSM 
   5 (26.3)
 0 (0.0)
 14 (73.3)
 4 (28.6)
 2 (14.3)
 8 (57.1) 
 1.000
 0.172
 0.459
Hepatitis C   1 (5.3) 4 (28.6) 0.138
On HAART   18 (94.7) 14 (100.0) 1.000
Total number of HBV
  vaccination median 
  (IQR) 
    6.0 (6.0–7.0)   6.0 (6.0–6.3) 0.360
CD4 baseline
CD4 follow-up
   CD4 >500 
     425 (333–610)
     465 (287–607)
  4 (21.1)
   386 (290–535)
   465 (273–594)
 3 (21.4)
0.308
0.855
 1.000
Log10 HIV baseline
Log10 HIV follow-up
   HIVvl <50 copies 
1.699 
(1.699–2.057)
1.699 
(1.699–1.919)
 11 (57.9)
1.922 
(1.699–2.867)
1.766 
(1.699–2.253)
 3 (21.4)
0.103
0.375
0.036
Values are presented as median (IQR) or number (%).
HBV, hepatitis B virus; IQR, interquartile range; Hetero, heterosexual 
contact; IVDU, intravenous drug abuse; MSM, men who have sex 
with men; HAART, highly active antiretroviral therapy; Hepatitis C, 
hepatitis C co-infection; total number of HBV vaccinations, includes 
the conventional standard-dose HBV vaccination and the double-
dose HBV rescue vaccination; CD4 baseline and follow-up, CD4 T-
cell cell count cells/mm
3 median (IQR) at baseline and follow-up, re-
spectively; CD4 >500, patients who had CD4 T-cell counts at baseline 
>500 and at follow-up >500; Log10 HIV baseline and follow-up, Log 10 HIV 
viral load copies/mL at baseline and follow-up, respectively; HIVvl 
<50 copies, patients who had HIV viral load <50 at both baseline and 
follow-up.
Table 3. Logistic Regression of Variables Associated with Persistent 
Responders (PR) at One-Year Follow-Up after Completion of Three 
Double-Dose Hepatitis B Rescue Vaccinations 
Variable OR (95% CI)  p-value
Sex
  Female (ref)
  Male  11.329 (0.054–2392.338)  0.374
HIV risk factor
  Hetero (ref)
  IVDU
  MSM
   0.000 (0.000- .)
   0.541 (0.004–72.406)
 0.999
 0.806
Hepatitis C co-infection
  Hepatitis C positive (ref)
  No hepatitis C  25.933 (0.977–688.251)  0.052
HAART
  No HAART (ref)
  On HAART     0.000 (0.000- .)  1.000 
CD4 T-cell count
  CD4 ≤500 (ref)
  CD4 >500     0.387 (0.047–3.179)   0.377
HIV viral load
  HIV viral load >50 (ref)
  HIV viral load <50   12.973 (1.189–141.515)  0.036
OR, odds ratio; CI, confidence interval; IQR, interquartile range; Het-
ero, heterosexual contact; IVDU, intravenous drug abuse; MSM, men 
who have sex with men; HAART, highly active antiretroviral therapy; 
CD4 ≤500, patients who had CD4 T-cell count ≤500 either at baseline 
or follow-up; CD4 >500, patients who had CD4 T-cell count >500 
both at baseline and follow-up; HIV viral load >50, patients who had 
detectable HIV viral load >50  either at baseline or follow-up; HIV vi-
ral load <50, patients who had undetectable HIV viral load <50 both 
at baseline and follow-up.90  Gut and Liver, Vol. 6, No. 1, January 2012
not different between those with waning or persistent vaccine 
responses. It is also interesting that of those vaccine responders 
who had developed acute HBV infection, none of them devel-
oped chronic HBV infection, suggesting benefit from positive 
response from HBV vaccination for at least 7 years of follow-
up.
24 Also long-term memory B cells specific for hepatitis B 
surface antigen were found in HIV-infected patients with serum 
anti-HBs titer less than 10 mIU/mL.
25 Therefore, there could be 
still some benefit for protection against HBV infection even if 
protective levels of anti-HBs titers may decrease after success-
ful response to double-dose HBV rescue vaccination in HIV-
infected patients. 
Our study has limitations, however, mostly stemming from 
its small sample size and its retrospective nature. Eleven of 44 
double-dose HBV rescue vaccine responders were not available 
for one year follow-up evaluation, which might have affected 
assessment of the durability of persistent protective anti-HBs 
titers in double-dose HBV rescue vaccine responders. Although 
factors such as the level of CD4 T-cell count,
26 HAART,
27 and 
MSM
28 were shown to be associated with HBV vaccine response 
in HIV-infected patients, our study did not show significant 
association between these factors and persistence of protective 
anti-HBs titers. This might reflect one of limitations based on 
the small sample size due to retrospective nature, not true ab-
sence of association. Nonetheless, our cohort of patients might 
well represent urban HIV-infected patients with access to HIV 
care in the developed world such as the United States. Therefore, 
this study results should be of assistance to manage HBV vac-
cination in urban HIV-infected patients in the developed world. 
In conclusion, double-dose HBV rescue vaccination in HIV-
infected patients has demonstrated a higher seroconversion rate 
of protective anti-HBs titers. Protective levels of anti-HBs titers 
may decrease over time after successful double-dose HBV res-
cue vaccination. Optimizing HIV viral load suppression could 
improve the persistence of protective anti-HBs titers. Achiev-
ing protective levels of anti-HBs titers in HIV-infected patients, 
even if protective levels of anti-HBs titers are decreased, might 
conceivably provide important protection against chronic HBV 
infection, and double-dose HBV rescue vaccination should be 
considered in HIV-infected patients who never responded to 
conventional or booster HBV vaccination series. Further studies 
involving a larger number of patients are needed to define the 
best strategies for improving immune response to HBV vaccina-
tion in HIV-infected patients.
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